Please login to the form below

Not currently logged in
Email:
Password:

US regulatory science awards announced

The US National Institutes of Health and the US Food and Drug Administration will partner on a scheme to award research projects in regulatory science

The US National Institutes of Health (NIH) and the US Food and Drug Administration (FDA) will partner on a scheme to award four research projects in regulatory science.

The NIH will award $9.4m over three years to projects which "better inform scientists and regulatory reviewers alike about medical product safety, and improve the evaluation and availability of new medical products to the community." The FDA will contribute $950,000 to the scheme.

Projects set to be recipients of the award include research by Dr Dennis E Hourcade on nanoparticles and work by researchers at the University of Michigan into innovative clinical trial design.

The other two projects are the development of an innovative heart/lung model by Dr Donald E Ingber, Harvard University Medical School, to test drug safety, and MB Research Laboratories' novel strategy to predict eye irritation.

"These four projects were chosen among many applications because they were the most meritorious proposals for addressing high priority areas in cutting-edge biomedical research and regulatory science," said NIH director, Dr Francis S Collins.

He continued: "This partnership marks the beginning of our work with the FDA to use new scientific and technological tools to aid/enhance the review of new drugs and devices. It is one facet of our shared commitment to speed the delivery of new medical products to patients."

The awards continue a commitment from both agencies made in February 2010 to work together on important public health issues under the NIH-FDA Joint Leadership Council.

29th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics